tdap
Phase 2- Indications
- Alzheimer's disease
Company intelligence / Profile preview
Mindful Diagnostics and Therapeutics is conducting a Phase 1/2 clinical trial evaluating the impact of Tdap vaccination on plasma biomarkers associated with Alzheimer's disease. The study aims to determine whether Tdap immunization can influence levels of amyloid, tau, and neurofilament light protein—key markers for neurodegeneration—and immune parameters in adults at risk for dementia. The company is exploring less invasive diagnostic alternatives to traditional Alzheimer's testing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Mindful Diagnostics and Therapeutics, LLC.